{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:17:36Z","timestamp":1794410256223,"version":"4.9.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-025-05545-x","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T17:49:02Z","timestamp":1753984142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting high circulating dipeptidyl peptidase 3 in circulatory failure"],"prefix":"10.1186","volume":"29","author":[{"given":"Adrien","family":"Picod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feriel","family":"Azibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veli-Pekka","family":"Harjola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahir","family":"Karakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Kimmoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pickkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thiele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mebazaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"2","key":"5545_CR1","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.bja.2021.11.021","volume":"128","author":"B Deniau","year":"2022","unstructured":"Deniau B, Picod A, Van Lier D, Vaittinada Ayar P, Santos K, Hartmann O, et al. High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the international, prospective and observational FROG-ICU cohort. Br J Anaesth. 2022;128(2):e54\u20137.","journal-title":"Br J Anaesth"},{"issue":"1","key":"5545_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13054-020-02888-5","volume":"24","author":"F D\u00e9pret","year":"2020","unstructured":"D\u00e9pret F, Amzallag J, Pollina A, Fayolle-Pivot L, Coutrot M, Chaussard M, et al. Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients. Crit Care Lond Engl. 2020;24(1):168.","journal-title":"Crit Care Lond Engl"},{"issue":"2","key":"5545_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/ejhf.1601","volume":"22","author":"B Deniau","year":"2020","unstructured":"Deniau B, Rehfeld L, Santos K, Dienelt A, Azibani F, Sadoune M, et al. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 Inhibition rapidly and sustainably improves haemodynamics. Eur J Heart Fail. 2020;22(2):290\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"5545_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/ejhf.1600","volume":"22","author":"K Takagi","year":"2020","unstructured":"Takagi K, Blet A, Levy B, Deniau B, Azibani F, Feliot E, et al. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial. Eur J Heart Fail. 2020;22(2):279\u201386.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"5545_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cardfail.2024.03.014","volume":"31","author":"A Picod","year":"2025","unstructured":"Picod A, Nordin H, Jarczak D, Zeller T, Oddos C, Santos K, et al. High Circulating dipeptidyl peptidase 3 predicts mortality and need for organ support in cardiogenic shock: an ancillary analysis of the ACCOST-HH trial. J Card Fail. 2025;31(1):29\u201336.","journal-title":"J Card Fail"},{"issue":"1","key":"5545_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13054-021-03471-2","volume":"25","author":"A Blet","year":"2021","unstructured":"Blet A, Deniau B, Santos K, van Lier DPT, Azibani F, Wittebole X, et al. Monitoring Circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Crit Care Lond Engl. 2021;25(1):61.","journal-title":"Crit Care Lond Engl"},{"issue":"3","key":"5545_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0885-4505(88)90133-8","volume":"40","author":"Y Shimamori","year":"1988","unstructured":"Shimamori Y, Watanabe Y, Fujimoto Y. Human placental dipeptidyl aminopeptidase III: hydrolysis of enkephalins and its stimulation by cobaltous ion. Biochem Med Metab Biol. 1988;40(3):305\u201310.","journal-title":"Biochem Med Metab Biol"},{"issue":"3","key":"5545_CR8","first-page":"257","volume":"52","author":"H Sato","year":"2003","unstructured":"Sato H, Kimura K, Yamamoto Y, Hazato T. [Activity of DPP III in human cerebrospinal fluid derived from patients with pain]. Masui. 2003;52(3):257\u201363.","journal-title":"Masui"},{"issue":"6","key":"5545_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1373\/jalm.2018.027995","volume":"3","author":"L Rehfeld","year":"2019","unstructured":"Rehfeld L, Funk E, Jha S, Macheroux P, Melander O, Bergmann A. Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples. J Appl Lab Med. 2019;3(6):943\u201353.","journal-title":"J Appl Lab Med"},{"key":"5545_CR10","doi-asserted-by":"publisher","first-page":"154383","DOI":"10.1016\/j.jcrc.2023.154383","volume":"78","author":"D van Lier","year":"2023","unstructured":"van Lier D, Beunders R, Kox M, Pickkers P. Associations of dipeptidyl-peptidase 3 with short-term outcome in a mixed admission ICU-cohort. J Crit Care. 2023;78:154383.","journal-title":"J Crit Care"},{"issue":"1","key":"5545_CR11","doi-asserted-by":"crossref","first-page":"00342","DOI":"10.1183\/23120541.00342-2022","volume":"9","author":"D van Lier","year":"2023","unstructured":"van Lier D, Deniau B, Santos K, Hartmann O, Dudoignon E, Depret F, et al. Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study. ERJ Open Res. 2023;9(1):00342\u20132022.","journal-title":"ERJ Open Res"},{"issue":"9","key":"5545_CR12","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1111\/febs.16429","volume":"290","author":"G Malovan","year":"2023","unstructured":"Malovan G, Hierzberger B, Suraci S, Schaefer M, Santos K, Jha S, et al. The emerging role of dipeptidyl peptidase 3 in pathophysiology. FEBS J. 2023;290(9):2246\u201362.","journal-title":"FEBS J"},{"issue":"1","key":"5545_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1515\/bchm3.1988.369.1.29","volume":"369","author":"M Abrami\u0107","year":"1988","unstructured":"Abrami\u0107 M, Zubanovi\u0107 M, Vitale L. Dipeptidyl peptidase III from human erythrocytes. Biol Chem Hoppe Seyler. 1988;369(1):29\u201338.","journal-title":"Biol Chem Hoppe Seyler"},{"issue":"3","key":"5545_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1161\/HYPERTENSIONAHA.116.07357","volume":"68","author":"X Pang","year":"2016","unstructured":"Pang X, Shimizu A, Kurita S, Zankov DP, Takeuchi K, Yasuda-Yamahara M, et al. Novel therapeutic role for dipeptidyl peptidase III in the treatment of hypertension. Hypertension. 2016;68(3):630\u201341.","journal-title":"Hypertension"},{"issue":"40","key":"5545_CR15","doi-asserted-by":"publisher","first-page":"13711","DOI":"10.1074\/jbc.RA120.014183","volume":"295","author":"S Jha","year":"2020","unstructured":"Jha S, Taschler U, Domenig O, Poglitsch M, Bourgeois B, Pollheimer M, et al. Dipeptidyl peptidase 3 modulates the renin-angiotensin system in mice. J Biol Chem. 2020;295(40):13711\u201323.","journal-title":"J Biol Chem"},{"key":"5545_CR16","doi-asserted-by":"crossref","unstructured":"Picod A, Placier S, Genest M, Callebert J, Julian N, Zalc M et al. Circulating Dipeptidyl Peptidase 3 Modulates Systemic and Renal Hemodynamics Through Cleavage of Angiotensin Peptides. Hypertens Dallas Tex. 1979. 2024.","DOI":"10.1161\/HYPERTENSIONAHA.123.21913"},{"key":"5545_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.peptides.2016.06.005","volume":"83","author":"N Cruz-Diaz","year":"2016","unstructured":"Cruz-Diaz N, Wilson BA, Pirro NT, Brosnihan KB, Marshall AC, Chappell MC. Identification of dipeptidyl peptidase 3 as the Angiotensin-(1-7) degrading peptidase in human HK-2 renal epithelial cells. Peptides. 2016;83:29\u201337.","journal-title":"Peptides"},{"issue":"12","key":"5545_CR18","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1515\/BC.2000.151","volume":"381","author":"M Abrami\u0107","year":"2000","unstructured":"Abrami\u0107 M, Schleuder D, Dolovcak L, Schr\u00f6der W, Strupat K, Sagi D, et al. Human and rat dipeptidyl peptidase III: biochemical and mass spectrometric arguments for similarities and differences. Biol Chem. 2000;381(12):1233\u201343.","journal-title":"Biol Chem"},{"issue":"4","key":"5545_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1515\/hsz-2014-0247","volume":"396","author":"M Abrami\u0107","year":"2015","unstructured":"Abrami\u0107 M, Kara\u010di\u0107 Z, \u0160emanjski M, Vukeli\u0107 B, Jaj\u010danin-Jozi\u0107 N. Aspartate 496 from the subsite S2 drives specificity of human dipeptidyl peptidase III. Biol Chem. 2015;396(4):359\u201366.","journal-title":"Biol Chem"},{"issue":"3","key":"5545_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1515\/BC.2007.039","volume":"388","author":"M Barsun","year":"2007","unstructured":"Barsun M, Jajcanin N, Vukeli\u0107 B, Spoljari\u0107 J, Abrami\u0107 M. Human dipeptidyl peptidase III acts as a post-proline-cleaving enzyme on endomorphins. Biol Chem. 2007;388(3):343\u20138.","journal-title":"Biol Chem"},{"issue":"17","key":"5545_CR21","doi-asserted-by":"publisher","first-page":"6525","DOI":"10.1073\/pnas.1118005109","volume":"109","author":"GA Bezerra","year":"2012","unstructured":"Bezerra GA, Dobrovetsky E, Viertlmayr R, Dong A, Binter A, Abramic M, et al. Entropy-driven binding of opioid peptides induces a large domain motion in human dipeptidyl peptidase III. Proc Natl Acad Sci U S A. 2012;109(17):6525\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5545_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2796.1993.tb00647.x","volume":"233","author":"G Berglund","year":"1993","unstructured":"Berglund G, Elmst\u00e4hl S, Janzon L, Larsson SA. The Malmo diet and Cancer study. Design and feasibility. J Intern Med. 1993;233(1):45\u201351.","journal-title":"J Intern Med"},{"issue":"6","key":"5545_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1365-2796.1996.483819000.x","volume":"239","author":"G Berglund","year":"1996","unstructured":"Berglund G, Eriksson KF, Israelsson B, Kjellstr\u00f6m T, Lindg\u00e4rde F, Mattiasson I, et al. Cardiovascular risk groups and mortality in an urban Swedish male population: the Malm\u00f6 preventive project. J Intern Med. 1996;239(6):489\u201397.","journal-title":"J Intern Med"},{"issue":"1","key":"5545_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13613-024-01325-y","volume":"14","author":"A Picod","year":"2024","unstructured":"Picod A, Garcia B, Van Lier D, Pickkers P, Herpain A, Mebazaa A, et al. Impaired angiotensin II signaling in septic shock. Ann Intensive Care. 2024;14(1):89.","journal-title":"Ann Intensive Care"},{"issue":"4","key":"5545_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1164\/rccm.202010-3873LE","volume":"203","author":"A Picod","year":"2021","unstructured":"Picod A, Deniau B, Vaittinada Ayar P, Genest M, Julian N, Azibani F, et al. Alteration of the Renin-Angiotensin-Aldosterone system in shock: role of the dipeptidyl peptidase 3. Am J Respir Crit Care Med. 2021;203(4):526\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"5545_CR26","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419\u201330.","journal-title":"N Engl J Med"},{"issue":"1","key":"5545_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13613-019-0536-5","volume":"9","author":"KR Ham","year":"2019","unstructured":"Ham KR, Boldt DW, McCurdy MT, Busse LW, Favory R, Gong MN, et al. Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial. Ann Intensive Care. 2019;9(1):63.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"5545_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13054-020-2733-x","volume":"06","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Wunderink RG, Szerlip H, English SW, Busse LW, Deane AM, et al. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock. Crit Care Lond Engl. 2020;06(1):43.","journal-title":"Crit Care Lond Engl"},{"issue":"1","key":"5545_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40635-024-00638-3","volume":"12","author":"B Garcia","year":"2024","unstructured":"Garcia B, Ter Schiphorst B, Santos K, Su F, Dewachter L, Vasques-N\u00f3voa F, et al. Inhibition of Circulating dipeptidyl-peptidase 3 by Procizumab in experimental septic shock reduces catecholamine exposure and myocardial injury. Intensive Care Med Exp. 2024;12(1):53.","journal-title":"Intensive Care Med Exp"},{"key":"5545_CR30","doi-asserted-by":"crossref","unstructured":"Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW et al. Renin and survival in patients given angiotensin II for Catecholamine-Resistant vasodilatory shock. Am J Respir Crit Care Med. 2020.","DOI":"10.1164\/rccm.201911-2172OC"},{"key":"5545_CR31","doi-asserted-by":"crossref","unstructured":"Wenzl FA, Bruno F, Kraler S, Klingenberg R, Akhmedov A, Ministrini S, et al. Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes. Eur Heart J. 2023. ehad545.","DOI":"10.1093\/eurheartj\/ehad545"},{"issue":"8","key":"5545_CR32","doi-asserted-by":"publisher","first-page":"e0238039","DOI":"10.1371\/journal.pone.0238039","volume":"15","author":"B Deniau","year":"2020","unstructured":"Deniau B, Blet A, Santos K, Vaittinada Ayar P, Genest M, K\u00e4storf M, et al. Inhibition of Circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept study. PLoS ONE. 2020;15(8):e0238039.","journal-title":"PLoS ONE"},{"key":"5545_CR33","doi-asserted-by":"publisher","unstructured":"AdrenOSS-1 study investigators, Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman BG et al. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care [Internet]. 2018 Dec [cited 2018 Dec 28];22(1). Available from: https:\/\/ccforum.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13054-018-2243-2","DOI":"10.1186\/s13054-018-2243-2"},{"issue":"11","key":"5545_CR34","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s00134-021-06537-5","volume":"47","author":"PF Laterre","year":"2021","unstructured":"Laterre PF, Pickkers P, Marx G, Wittebole X, Meziani F, Dugernier T, et al. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial. Intensive Care Med. 2021;47(11):1284\u201394.","journal-title":"Intensive Care Med"},{"issue":"3","key":"5545_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S2213-2600(21)00439-2","volume":"10","author":"M Karakas","year":"2022","unstructured":"Karakas M, Akin I, Burdelski C, Clemmensen P, Grahn H, Jarczak D, et al. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. Lancet Respir Med. 2022;10(3):247\u201354.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"5545_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/ejhf.260","volume":"17","author":"VP Harjola","year":"2015","unstructured":"Harjola VP, Lassus J, Sionis A, K\u00f8ber L, Tarvasm\u00e4ki T, Spinar J, et al. Clinical picture and risk prediction of short-term mortality in cardiogenic shock. Eur J Heart Fail. 2015;17(5):501\u20139.","journal-title":"Eur J Heart Fail"},{"issue":"25","key":"5545_CR37","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","volume":"377","author":"H Thiele","year":"2017","unstructured":"Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI strategies in patients with acute myocardial infarction and cardiogenic shock. N Engl J Med. 2017;377(25):2419\u201332.","journal-title":"N Engl J Med"},{"issue":"2","key":"5545_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2018.04.051","volume":"72","author":"B Levy","year":"2018","unstructured":"Levy B, Clere-Jehl R, Legras A, Morichau-Beauchant T, Leone M, Frederique G, et al. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol. 2018;72(2):173\u201382.","journal-title":"J Am Coll Cardiol"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05545-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-025-05545-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-025-05545-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:11:45Z","timestamp":1757322705000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-025-05545-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5545"],"URL":"https:\/\/doi.org\/10.1186\/s13054-025-05545-x","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AP reports having received research grants from the Soci\u00e9t\u00e9 de R\u00e9animation de Langue Fran\u00e7aise (SRLF), the Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie R\u00e9animation (SFAR), the Zoll Fondation, the Fonds pour la chirurgie cardiaque and 4TEEN4 Pharmaceuticals GmbH. MK is supported by the Else Kroener-Fresenius-Stiftung (W3 Else Kroener Clinician Scientist Professorship). He reports grant and non-financial support from Adrenomed AG and CSL Vifor, as well as personal fees from Adrenomed AG, Sphingotec GmbH, CSL Vifor, Daiichi-Sankyo, Pharmacosmos and 4TEEN4 Pharmaceuticals GmbH. PP has received research grants, travel and consultancy reimbursements from 4TEEN4 Pharmaceuticals GmbH. UZ received speaker honoraria form 4TEEN4 Pharmaceuticals. KS is employed as chief scientific officer at 4TEEN4 Pharmaceuticals GmbH. AM reports personal fees from Orion, Roche, Adrenomed and Fire 1, and grants and personal fees from 4TEEN4 Pharmaceuticals GmbH, Abbott, Roche, and Sphingotec GmbH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"340"}}